Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

Summary

This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration

Timeline

Start

2005-12

Primary completion

—

Completion

2006-08

Drugs

Indications